+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Zogenix Inc (ZGNX) - Financial and Strategic SWOT Analysis Review

  • ID: 4278387
  • SWOT Analysis
  • May 2021
  • GlobalData
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

FEATURED COMPANIES

  • Biocodex
  • Encoded Therapeutics Inc
  • EpyGenix Therapeutics Inc
  • GW Pharmaceuticals Plc
  • NeuCyte Inc
  • Ovid Therapeutics Inc
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Zogenix Inc (ZGNX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Zogenix Inc (Zogenix) develops and markets therapies for the treatment of patients with rare diseases. The company’s marketed product include Fintepla (fenfluramine) approved in the US, the UK and EU for the treatment of dravet syndrome. Its pipeline product candidate include MT1621, an investigational deoxynucleoside combination therapy for the treatment of thymidine kinase 2 deficiency (TK2d); Fintepla for Lennox-Gastaut syndrome (LGS) and other rare epilepsies; and gene therapies for dravet syndrome and other epilepsy disorders. The company through its subsidiaries operates in the US, the UK, Germany, Ireland, Japan, France and Italy. Zogenix is headquartered in Emeryville, California, the US.

Zogenix Inc Key Recent Developments
  • May 06, 2021: Zogenix provides corporate update and reports first quarter 2021 financial results
  • Mar 02, 2021: Zogenix to Participate in the Raymond James Institutional Investors Conference
  • Feb 18, 2021: Zogenix to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
  • Feb 11, 2021: Zogenix to Release Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call and Webcast on February 25
  • Jan 11, 2021: Zogenix announces preliminary, unaudited fourth quarter 2020 net product sales

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Biocodex
  • Encoded Therapeutics Inc
  • EpyGenix Therapeutics Inc
  • GW Pharmaceuticals Plc
  • NeuCyte Inc
  • Ovid Therapeutics Inc

Section 1 - About the Company
  • Zogenix Inc - Key Facts
  • Zogenix Inc - Key Employees
  • Zogenix Inc - Key Employee Biographies
  • Zogenix Inc - Major Products and Services
  • Zogenix Inc - History
  • Zogenix Inc - Company Statement
  • Zogenix Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries

Section 2 - Company Analysis
  • Company Overview
  • Zogenix Inc - Business Description
  • Other Break-up: Collaboration Revenue
  • Performance
  • Other Break-up: Net Product Sales
  • Performance
  • R&D Overview
  • Zogenix Inc - Corporate Strategy
  • Zogenix Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Zogenix Inc - Strengths
  • Zogenix Inc - Weaknesses
  • Zogenix Inc - Opportunities
  • Zogenix Inc - Threats
  • Zogenix Inc - Key Competitors

Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts

Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
  • Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
  • Zogenix Inc, Recent Deals Summary

Section 5 - Company’s Recent Developments
  • May 06, 2021: Zogenix provides corporate update and reports first quarter 2021 financial results
  • Mar 02, 2021: Zogenix to Participate in the Raymond James Institutional Investors Conference
  • Feb 18, 2021: Zogenix to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
  • Feb 11, 2021: Zogenix to Release Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call and Webcast on February 25
  • Jan 11, 2021: Zogenix announces preliminary, unaudited fourth quarter 2020 net product sales
  • Sep 21, 2020: Zogenix appoints three industry leaders to its Board of Directors
  • Aug 05, 2020: Zogenix provides corporate update and reports second quarter 2020 financial results
  • Jun 12, 2020: Zogenix introduces new resources for Dravet Syndrome siblings
  • May 05, 2020: Zogenix provides corporate update and reports first quarter 2020 financial results
  • Apr 20, 2020: Zogenix appoints Shawnte Mitchell as Executive Vice President, General Counsel & Secretary

Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact Us
  • Disclaimer

List of Tables
  • Zogenix Inc, Key Facts
  • Zogenix Inc, Key Employees
  • Zogenix Inc, Key Employee Biographies
  • Zogenix Inc, Major Products and Services
  • Zogenix Inc, History
  • Zogenix Inc, Subsidiaries
  • Zogenix Inc, Key Competitors
  • Zogenix Inc, Ratios based on current share price
  • Zogenix Inc, Annual Ratios
  • Zogenix Inc, Interim Ratios
  • Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
  • Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
  • Zogenix Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios

List of Figures
  • Zogenix Inc, Performance Chart (2016 - 2020)
  • Zogenix Inc, Ratio Charts
  • Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
  • Zogenix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021
Note: Product cover images may vary from those shown

Loading
LOADING...

A selection of companies mentioned in this report includes:

  • Wellstat Therapeutics Corp
  • Supernus Pharmaceuticals Inc
  • Stoke Therapeutics Inc
  • Stealth BioTherapeutics Corp
  • Sarepta Therapeutics Inc
  • Reneo Pharmaceuticals Inc
  • Reata Pharmaceuticals Inc
  • PTC Therapeutics Inc
  • Ovid Therapeutics Inc
  • NeuroCycle Therapeutics Inc
  • Neurocrine Biosciences Inc
  • NeuCyte Inc
  • Metro International Biotech LLC
  • GW Pharmaceuticals Plc
  • EpyGenix Therapeutics Inc
  • Encoded Therapeutics Inc
  • Biocodex
Note: Product cover images may vary from those shown